Patent · US Active

Highly selective c-Met inhibitors as anticancer agents

US9695175B2 · kind B2 · utility

0Cited by

0References

35Claims

0Family size

Assignee

CB Therapeutics, Inc. · US

Inventors

Boyu Zhong · Carmel, US
Chuan Shih · Carmel, US
Hongbin Yuan · Shanghai, CN
Feng Zhou · Shanghai, CN

Key dates

Filing date	Aug 1, 2013
Grant date	Jul 4, 2017
Priority date	—
Expiry date	Aug 1, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.